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Parents often overreport adherence to asthma treatment regimens making accurate assessment of medication adherence in clinical
practice diﬃcult. This study was conducted to compare two adherence assessment methods clinicians may choose from when
assessing patient inhaled corticosteroid (ICS) adherence: parental report and dose counter measurements of metered-dose inhaler
(MDI) actuation. Participants included children (N = 50) with persistent asthma and their parents (N = 50). At enrollment,
children received a new, marked ICS at the dose prescribed by their physician. Thirty days following enrollment, we measured ICS
adherence by parental report and objectively, with a dose counter. Parental report overestimated ICS adherence when compared to
dose counter. We found a statistically signiﬁcant overall diﬀerence between parental report and objectively measured adherence. A
dose counter that most ICS inhalers are equipped with may be a more reliable alternative measure of ICS adherence in a clinical
practice setting.
1.Introduction
Asthma disproportionately burdens low-income African-
American and Hispanic children residing in inner cities
such as the Bronx, New York [1]. The Bronx, which is pre-
dominately Hispanic, is the New York City (NYC) borough
with the highest overall rates of asthma hospitalizations,
deaths, and prevalence among children and adults [2].
Daily use of inhaled corticosteroid (ICS) medications, the
most eﬀective long-term therapy available for patients with
persistent asthma, controls symptoms and reduces asthma
morbidity [3]. However, adherence to ICS is about 50%
for children with asthma [4–7]. Poor adherence to ICS
medications contributes to asthma morbidity and has been
associated with increased health-care use and decreased
treatment eﬀectiveness [3]. Improving adherence in clinical
practice setting is diﬃcult because health-care providers do
notknowifpatientsareadherentwithouttheuseofobjective
monitoring [8].
Electronic devices attached to inhalers record date and
timeofmedicationuseandprovideobjectivedocumentation
of adherence [9]. However, these devices are costly [10]
and prone to mechanical failure [11, 12], making them
impractical for oﬃce or clinic practices. In turn, many
pediatricians rely on parental report of ICS adherence
to guide asthma management in children with persistent
asthma [13]. Subjective measures are easily administered
and cost-eﬀective,yet often provide overestimated adherence
data that may result in unnecessary escalation of treatment
[9]. National guidelines recommend that clinicians assess
and encourage adherence to recommended therapy during
all asthma visits [14]; however, no single successful method
of objectively measuring medication adherence in clinical
practice has been identiﬁed due to a lack of evidence [14].
Recently, several manufacturers have begun to incorpo-
rate dose counters into their inhalation delivery devices [15].
Phase III open-label studies in children and adults with
asthma and chronic obstructive pulmonary disease (COPD)2 Journal of Allergy
established clinical functionality, patient satisfaction, and
relative accuracy of inhalers with integrated dose counters
[15–18]. These studies enrolled patients who were at least
90% compliant with study medication during the screening
period [15–18]. There is a lack of literature comparing ICS
adherence measured by parental report to that measured
by the integrated dose counter in a clinical practice setting.
Thus,theobjectiveofourstudywastocomparetwomethods
of measuring ICS adherence from which clinicians may
choose when assessing patient adherence: parental report
and dose counter measurements of metered-dose inhaler
(MDI) actuation.
2.MaterialsandMethods
We conducted a one-month prospective observational study
of 50 low-income, minority children aged 2 to 9 years with
physician-diagnosed medically treated persistent asthma
who have been prescribed ICS with an integrated dose
counter (such as ﬂuticasone propionate hydroﬂuoroalkane
(HFA) inhalation aerosol (Flovent HFA) or ﬂuticasone
propionate/salmeterol HFA inhalation aerosol (Advair HFA)
and their parents or primary caregivers. Thirty-four (68%)
of children have been prescribed Flovent HFA 44 mcg two
puﬀs twice daily, 14 (28%) Flovent HFA 110 mcg two puﬀs
twice daily, 1 (2%) Advair HFA 115/21 2 puﬀs twice daily,
and 1 (2%) Advair HFA 230/21 2 puﬀs twice daily by
their physician prior to the study enrollment. Twenty-ﬁve
(50%) of children were also prescribed leukotriene receptor
antagonist (such as Montelukast (Singulair) 4mg or 5mg
daily) prior to the study enrollment. Children remained on
the prescribed medication regimen, including the dose and
preparation, for the duration of the study.
Other study eligibility criteria included: (1) children
with at least one acute or same day clinic visit for asthma,
Emergency Department (ED) visit, or a hospitalization for
asthma in the past 12 months; (2) if the child is 2 years of age
at the time of the recruitment, he/she must have at least two
prior episodes of wheezing treated and reversible with beta-
agonists; (3) primary caregiver speaks English or Spanish;
(4) family has a phone. Primary caregiver was deﬁned as an
adult who has primary custody of a child and with whom
the child spends at least 75% of the week. Although primary
caregivermaynotbethesubject’sparent,weusedtheseterms
interchangeably. Children with other chronic pulmonary
diseases(e.g,cysticﬁbrosis,bronchopulmonarydysplasia)or
presence of tracheostomy were excluded.
Study was approved by the Monteﬁore Medical Center
Institutional Review Board (IRB). Written caregiver consent
and child assent were obtained as per IRB guidelines. Fam-
ilies were recruited from two federally qualiﬁed Monteﬁore
Comprehensive Health Care Centers located in the poorest
section of the Bronx, NY where 27.9% of individuals are
below the US poverty level and asthma hospitalization rate
is almost twice the rate for NYC [2, 19]. At baseline, we
collected sociodemographic information and data about
asthma control using current National Asthma Education
and Prevention Program Guidelines for the Diagnosis and
Management of Asthma [14]. We reviewed child’s medical
records to determine if additional diagnoses of seasonal
allergies and/or eczema have been made by the physician.
All children have been prescribed ICS with an integrated
dose counter by their physician prior to study enrollment.
At enrollment, children received a new, marked ICS at the
physician-prescribed dose. Child’s health insurance covered
the cost of the ICS for 46/50 subjects. Four subjects had
a problem with their health insurance at the time of en-
rollment, and their ICS was provided by the project.
Parents were instructed to administer marked ICS as per
physicians’ orders (2 puﬀs twice a day). If used as directed,
120 actuations in the new inhaler suﬃce for 30 days of
treatment. Parents were asked to use only the marked ICS
inhaler for the duration of the study. Approximately thirty
days after enrollment (range 27–37 days, average 31 days),
we visited families at their homes where we administered
a survey to measure adherence by parental report and
retrieved a marked ICS inhaler that the child received at
enrollment.
2.1. Measures
2.1.1. Adherence Measured by Parental Report. During the
home visit parents were asked the following questions.
“During the past 4 weeks, did your child use the marked
inhaled corticosteroid pump (controller medication) for
his/her asthma?”; “how many puﬀs and how many times
a day did the child use the marked inhaled corticosteroid
pump in the past 4 weeks?”; “during the past 4 weeks,
how often did your child take marked inhaled corticosteroid
(controller medication)? (Answer choices included “every
day”, “almost every day”, “several times a week”, “once a
week”, and “less than once per week.”)
2.1.2. Adherence Measured Objectively by an Integrated Dose
Counter. The integrated dose counter is designed to count
downward to zero from the recommended number of
actuations and displays the number of actuations remaining
in the inhaler. The counter is built into the MDI canister and
cannot be reset. Additionally, the device has been engineered
to avoid undercounting [15]. We randomly tested 10% of
the canisters that we retrieved from the participants (after
the data on number of puﬀsw e r er e c o r d e d )a n df o u n d0 %
incidence of the MDI ﬁring but the counter not advancing.
To facilitate validity of dose counter data, parents were asked
about medication sharing or use of another unmarked ICS
at inhaler retrieval. Parents were unaware of the reason for
inhaler retrieval.
2.2. Statistical Analysis
2.2.1. Deﬁnitions. ICS adherence reported by parents was
coded as continuous variable: 100% when parents adminis-
tered ICS to their child “every day”; 75% “almost every day”;
50% “several times a week”; 25% “once a week”; 0% “less
than once a week”. Dose counter-measured adherence was
calculated as the number of puﬀs used relative to the number
of puﬀs expected to have been used at 30-day followup.Journal of Allergy 3
Complete adherence
according to method of assessment
0%
5%
10%
15%
20%
25%
30%
35%
40%
45%
Parental report Dose counter
42% (21/50)
C
o
m
p
l
e
t
e
 
a
d
h
e
r
e
n
c
e
 
(
1
0
0
%
)
Method of assessment
10% (5/50)
Figure 1: Comparison of two methods of assessment of ICS
adherence.
2.2.2. Data Analysis. Descriptive statistics, including means,
ranges, and standard deviations (SD) were calculated for all
variables. Wilcoxon signed-rank test, a nonparametric test
for paired data, was used to compare the two adherence
methods. The Spearman rank correlation coeﬃcient, a
nonparametric measure of statistical dependence between
two variables, was used to test for association between
objectivelymeasuredadherenceandparentalorchildageand
parental level of education. These nonparametric tests were
used because normality was not assumed. All analyses were
performed using two-tailed tests with α = 0.05. The data
were analyzed using SPSS V.19 (SPSS Inc., Chicago, Illinois).
3. Results andDiscussion
3.1. Results. A total of 50 children (mean age = 5.6 years (SD
1.9), mean duration of asthma diagnosis 3.9 years (median
4 years)) and their parents (N = 50, 96% mothers, mean
age = 32.6 (SD 6.9), 64% unemployed) participated. Table 1
shows sociodemographic characteristics of the study sample.
Asthma was not well controlled or very poorly controlled in
most children (N = 42) (Table 1). Parental report revealed
that only 17 (34%) children have ever been evaluated by a
pulmonologist (Table 1). Mean ICS adherence as measured
by a dose counter was 57.8% (SD 31), (median 60.7%,
range 0%–100%). Parental report overestimated complete
ICS adherence: 42% (N = 21) of parents reported being
100% adherent as compared to 10% (N = 5) being 100%
adherent as per dose counter (Figure 1). Parental report of
nonadherence was accurate: 4% (N = 2) of parents reported
0% adherence as compared to 6% (N = 3) having 0%
adherence as per dose counter (Figure 2). Wilcoxon signed-
rank test revealed a statistically signiﬁcant overall diﬀerence
between parental report and objectively measured adherence
(P<. 0001). No relationship was found between dose
counter-measured adherence and parental or child age (P =
.732 and P = .639, resp.) and parental level of education
(P = .834).
3.2. Discussion. The impact of poor ICS adherence on
asthma treatment outcomes and morbidity has been well
documented [3]. The National Heart, Lung, and Blood
Table 1: Sociodemographic characteristics of children (N = 50).
Characteristic N %
Gender
Male 33 66
Female 17 34
Race/ethnicity
Hispanica 34 68
African American/Black 9 18
Hispanic & African American/Black 6 12
Other race (Indian) 1 2
Asthma controlb
Well controlled 8 16
Not well controlled 21 42
Very poorly controlled 21 42
Diagnosed with seasonal allergiesc 36 72
Diagnosed with eczemac 11 22
Have been evaluated by a pulmonologist 17 34
Have been evaluated by an allergist 9 18
Single-parent household 19 38
Parental level of education
Less than high school 14 28
Graduated high school 15 30
1–3 years of college 15 30
4 years of college or more 6 12
Data in table have been obtained by parental self-report unless noted
otherwise.
aHispanic is asked as ethnicity rather than race question as per United States
Census Bureau criteria [19].
bAsthma control was assessed as per National Asthma Education and
Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis
and management of Asthma [14].
Well-controlled asthma: Symptoms ≤ 2 days/week; nighttime awakenings
≤1x/month; interference with normal activity—None; short-acting beta2-
agonistuseforsymptomcontrol≤2days/week;exacerbationsrequiringoral
systemic corticosteroids 0-1/year.
Not-well controlled asthma: Symptoms >2 days/week; nighttime awaken-
ings>1x/month;Interferencewithnormalactivity—Somelimitation;short-
acting beta2-agonist use for symptom control >2 days/week; exacerbations
requiring oral systemic corticosteroids 2-3/year.
Very poorly controlled asthma: Symptoms—throughout the day; nighttime
awakenings >1x/week; interference with normal activity—extremely lim-
ited; short-acting beta2-agonist use for symptom control—several times per
day; exacerbations requiring oral systemic corticosteroids >3/year.
cData obtained by medical record review.
Institute (NHLBI) Expert Panel Report 3 (EPR-3) recom-
mends that clinicians assess and encourage adherence to
medications using parental or self-report [14]. The accuracy
of self-report of medication treatment adherence has been
examined in many diseases and found to be highly variable
and often inaccurate [4, 20, 21]. For example, electronic
monitoring revealed that children with asthma used only
50% of prescribed ICS over 6 months, whereas the patients
and their parents reported over 80% adherence [4]. Our
ﬁnding of dose counter-measured ICS adherence of 57.8%
supports this earlier report. Moreover, parents in our
study overestimated ICS adherence but accurately reported
nonadherence.4 Journal of Allergy
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Figure 2:ComparisonoftwomethodsofassessmentofICSnonad-
herence.
In addition to self-report, several other adherence assess-
ment methods exist and have been used in clinical trials [8].
These methods diﬀer in the degree of accuracy and objectiv-
ity with which patient adherence can be evaluated [8]. How-
ever, no single successful method has been recommended
for use in clinical practice [14]. As a result, physicians rely
on parental or self-report of medication adherence often
leadingtoinappropriatediagnosticandtherapeuticdecisions
[13]. Integrated dose counter has recently been incorporated
in several ICS inhalers and found to be reliable [16]. The
dose counter not only provides patients with a reliable
method for determining the remaining number of puﬀs,
but also may provide clinicians with an objective means
of assessing adherence to medication [15]. However, there
are no published reports that compared the two adherence
methods in a clinical practice setting: adherence measured
by parental self-report and adherence measured objectively
with a dose counter.
Our study had several limitations. First, our study pop-
ulation was composed of inner-city, minority, poor, and
mainly Latino children and parents recruited from two
community health centers in the Bronx, NY and may not be
representative of all Latino families or minority families in
general. However, our study population is representative of
the Bronx, NY general population, whose racial distribution
in 2010 was about 54% Hispanic or Latino and 36% Black or
African American [19]. Second, proportion of children who
have been evaluated by an allergist and/or pulmonologist
was obtained by parental self-report and does not represent
the true number of children who have ever been referred
to these specialists by the child’s physician but never kept
the appointment. This information was not systematically
recorded in medical records. Third, integrated dose counters
do not provide date and time of MDI use which more expen-
sive, electronic monitors that attach externally to the canister
provide [15]. Several studies have documented problems
with accuracy of these externally attached electronic devices,
including loss of data due to battery drain and recording
of nonexistent doses [11, 22–24]. Integrated dose counter is
built into the MDI canister and does not require batteries
[15].
Evidence from our study indicates that parental report
was a nonreliable method for assessing ICS adherence.
However, parental report of nonadherence was accurate.
Physicians who care for patients with persistent asthma need
to have easy-to-use, cost-eﬀe c t i v e ,a n do b j e c t i v et o o lt om e a -
sure medication adherence in a clinical setting. Integrated
dose counter may be such a tool.
4. Conclusions
Accuracy of parental report in clinical practice is of concern
inlightofﬁndingsfromthisstudyandpriorstudiesrevealing
that inner-city parents of children with asthma frequently
overestimate medication adherence. A dose counter that
most ICS inhalers are equipped with may be a more reliable
alternative measure of ICS adherence in clinical practice.
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